Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

NCT00339040 ·Status: COMPLETED ·Phase: PHASE2

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

NCT04982614 ·Status: COMPLETED ·Phase: PHASE4

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

NCT06243666 ·Status: ACTIVE_NOT_RECRUITING

Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

NCT02740777 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

NCT01254643 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

NCT04708041 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

NCT01984697 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women

NCT04270773 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17

NCT02888418 ·Status: UNKNOWN ·Phase: PHASE1

The KEN SHE Study on HPV-vaccine Efficacy

NCT03675256 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)

NCT00365716 ·Status: COMPLETED ·Phase: PHASE2

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

NCT00798265 ·Status: TERMINATED ·Phase: PHASE1

Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV

NCT07303751 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

NCT03206255 ·Status: COMPLETED

Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging

NCT06632912 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV

NCT03284866 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

NCT01381575 ·Status: COMPLETED ·Phase: PHASE3

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

NCT00092547 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico

NCT01717118 ·Status: COMPLETED ·Phase: PHASE4

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

NCT00411749 ·Status: COMPLETED ·Phase: PHASE2

HPV Vaccine Integrated Service Implementation Research in Cameroon

NCT06683664 ·Status: NOT_YET_RECRUITING ·Phase: NA

3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China

NCT01427777 ·Status: UNKNOWN

A Phase I Study of Quadrivalent HPV Recombinant Vaccine

NCT03085381 ·Status: COMPLETED ·Phase: PHASE1

Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years

NCT07281677 ·Status: RECRUITING ·Phase: PHASE4

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

NCT00380367 ·Status: COMPLETED ·Phase: PHASE3